Evidence map›Paper›PMID 11376123›Full record

ReviewMolecular pathology : MP2001

IGF-I receptor signalling in transformation and differentiation.

B Valentinis, R Baserga

Open access · bronzeAbstract readReview
In one paragraph

Review in Molecular pathology : MP, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 2 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 2 syntheses or guidelines pooled it, 322 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. IGFBP-3 functions as a molecular switch that mediates mitochondrial and metabolic homeostasis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Current epidemiology of pancreatic cancer: Challenges and opportunities.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020
    Article
  13. Article
  14. Review
  15. Article
  16. Obesity and the Risk of Gastrointestinal Cancers.Digestive diseases and sciences · 2019
    Review
  17. Article
  18. Review
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

B ValentinisKimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, 624 BLSB, Philadelphia, PA 19107, USA.
R Baserga
Sidney Kimmel Cancer Center · USThomas Jefferson University · US

Funding

TRAIL Receptors in Apoptosis and CancerP01CA078890 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CALABRETTA, BRUNO · 1999 to 2007
$8.9M
NCI NIH HHS CA 78890NCI NIH HHS P01 CA078890
6 · The paper itself

Abstract

The type 1 insulin-like growth factor receptor (IGF-IR) sends several signals, some of which are contradictory. When the concentrations of insulin receptor substrate 1 (IRS-1), a major substrate of the IGF-IR, are high, the signal is mitogenic, anti-apoptotic, and can even cause malignant transformation. However, in the absence of IRS-1, the IGF-IR sends a differentiation signal, which leads to granulocytic differentiation in haemopoietic cells. The mitogenic signal of the IGF-IR/IRS-1 combination depends largely, but not exclusively, on the activation of the phosphatidylinositol-3 kinase (PI3K).

Indexed as

Cell Transformation, NeoplasticAnimalsApoptosisBiomarkersCell DifferentiationDown-RegulationHumansMicePeroxidasePhosphatidylinositol 3-KinasesReceptor, IGF Type 1Signal TransductionBiomarkersPeroxidasePhosphatidylinositol 3-KinasesReceptor, IGF Type 1

Identifiers

PMID11376123
PMCPMC1187050
OpenAlexW2018697055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.